<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220203</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-021</org_study_id>
    <nct_id>NCT04220203</nct_id>
  </id_info>
  <brief_title>Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Treatment Protocol of Tucatinib in Combination With Capecitabine and Trastuzumab in Patients With Previously Treated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide access to tucatinib in the United States before FDA&#xD;
      approval.&#xD;
&#xD;
      Participants will receive a combination treatment of capecitabine, trastuzumab, and&#xD;
      tucatinib. All treatments will be given on a 21 day cycle.&#xD;
&#xD;
      To learn more about this program, contact Seattle Genetics' Medical Information&#xD;
      (medinfo@seagen.com).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>HER2-positive Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>300 mg orally two times per day</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m^2 orally two times per day on Days 1-14 of each 21-day cycle</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by ISH or&#xD;
             FISH or IHC methodology&#xD;
&#xD;
          -  For patients WITHOUT presence or history of brain metastases, have received previous&#xD;
             treatment with trastuzumab, pertuzumab, and T-DM1&#xD;
&#xD;
          -  For patients WITH presence or history of brain metastases, have received previous&#xD;
             treatment with trastuzumab&#xD;
&#xD;
          -  Have progression of unresectable locally advanced or metastatic breast cancer after&#xD;
             last systemic therapy (as confirmed by treating physician), or be intolerant of last&#xD;
             systemic therapy&#xD;
&#xD;
          -  Have measurable disease or non-measurable disease assessable by standard of care&#xD;
             imaging methods&#xD;
&#xD;
          -  Have ECOG PS 0 or 1&#xD;
&#xD;
          -  Have a life expectancy of at least 6 months, in the opinion of the treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eligible for a tucatinib clinical trial&#xD;
&#xD;
          -  Disease recurrence within 3 months of last capecitabine for metastatic disease&#xD;
&#xD;
          -  History of allergic reactions to trastuzumab, capecitabine, or compounds chemically or&#xD;
             biologically similar to tucatinib, except for Grade 1 or 2 infusion related reactions&#xD;
             to trastuzumab that were successfully managed, or known allergy to one of the&#xD;
             excipients in the protocol drugs&#xD;
&#xD;
          -  Have received treatment with any systemic anti-cancer therapy (excluding hormonal&#xD;
             therapy), non-CNS radiation, or experimental agent ≤ 3 weeks of first dose of protocol&#xD;
             treatment or are currently participating in an interventional clinical trial. Have&#xD;
             received hormonal therapies &lt;1 week of the first dose of protocol treatment.&#xD;
&#xD;
          -  Have any toxicity related to prior cancer therapies that has not resolved to ≤ Grade&#xD;
             1, with the following exceptions:&#xD;
&#xD;
               -  Alopecia and neuropathy, which must have resolved to ≤ Grade 2&#xD;
&#xD;
               -  CHF, which must have been ≤ Grade 1 in severity at the time of occurrence, and&#xD;
                  must have resolved completely&#xD;
&#xD;
               -  Anemia, which must have resolved to ≤ Grade 2&#xD;
&#xD;
          -  Have clinically significant cardiopulmonary disease&#xD;
&#xD;
          -  Have known myocardial infarction or unstable angina within 6 months prior to first&#xD;
             dose of protocol treatment&#xD;
&#xD;
          -  Are known carriers of Hepatitis B or Hepatitis C or have other known chronic liver&#xD;
             disease with uncontrolled disease&#xD;
&#xD;
          -  Are known to be positive for HIV with uncontrolled disease&#xD;
&#xD;
          -  Are pregnant, breastfeeding, or planning a pregnancy&#xD;
&#xD;
          -  Require therapy with warfarin or other coumarin derivatives (non-coumarin&#xD;
             anticoagulants are allowed)&#xD;
&#xD;
          -  Have inability to swallow pills or significant gastrointestinal disease which would&#xD;
             preclude the adequate oral absorption of medications&#xD;
&#xD;
          -  Have used strong CYP2C8 inhibitor within 5 half-lives of the inhibitor, or have used a&#xD;
             CYP2C8 or CYP3A4 inducer within 5 day prior to start of tucatinib treatment.&#xD;
&#xD;
          -  Have known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
          -  Have evidence within 2 years of the start of protocol treatment of another malignancy&#xD;
             that required systemic treatment.&#xD;
&#xD;
        CNS Exclusion - patients must not have any of the following:&#xD;
&#xD;
          -  Any untreated brain lesions &gt; 2.0 cm in size, unless discussed with medical monitor&#xD;
             and approval for enrollment is given&#xD;
&#xD;
          -  Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at&#xD;
             a total daily dose of &gt; 2 mg of dexamethasone (or equivalent). However, patients on a&#xD;
             chronic stable dose of ≤ 2 mg total daily of dexamethasone (or equivalent) may be&#xD;
             eligible with discussion and approval by the medical monitor&#xD;
&#xD;
          -  Any brain lesion thought to require immediate local therapy, including (but not&#xD;
             limited to) a lesion in an anatomic site where increase in size or possible&#xD;
             treatment-related edema may pose risk to patient (e.g. brain stem lesions).&#xD;
&#xD;
          -  Known or suspected LMD as documented by the treating physician&#xD;
&#xD;
          -  Have poorly controlled (&gt; 1/week) generalized or complex partial seizures, or manifest&#xD;
             neurologic progression due to brain metastases notwithstanding CNS-directed therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

